The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial
Open accessAbstract
Background Findings of large randomised trials have shown that lowering LDL cholesterol with statins reduces vascular morbidity and mortality rapidly, but limited evidence exists about the long-term efficacy and safety of statin treatment. The aim of the extended follow-up of the Heart Protection Study (HPS) is to assess long-term efficacy and safety of lowering LDL cholesterol with statins, and here we report cause-specific mortality and major morbidity in the in-trial and post-trial periods.Methods 20,536 patients at high risk of vascular and non-vascular outcomes were allocated either 40 mg simvastatin daily or placebo, using minimised randomisation. Mean in-trial follow-up was 5·3 years (SD 1·2), and post-trial follow-up of surviving patients yielded a mean total duration of 11·0 years (SD 0·6). The primary outcome of the long-term follow-up of HPS was first post-randomisation major vascular event, and analysis was by intention to treat. This trial is registered with ISRCTN, number 48489393.Findings During the in-trial period, allocation to simvastatin yielded an average reduction in LDL cholesterol of 1·0 mmol/L and a proportional decrease in major vascular events of 23% (95% CI 19-28; p<0·0001), with significant divergence each year after the first. During the post-trial period (when statin use and lipid concentrations were similar in both groups), no further significant reductions were noted in either major vascular events (risk ratio [RR] 0·95 [0·89-1·02]) or vascular mortality (0·98 [0·90-1·07]). During the combined in-trial and post-trial periods, no significant differences were recorded in cancer incidence at all sites (0·98 [0·92-1·05]) or any particular site, or in mortality attributed to cancer (1·01 [0·92-1·11]) or to non-vascular causes (0·96 [0·89-1·03]).Interpretation More prolonged LDL-lowering statin treatment produces larger absolute reductions in vascular events. Moreover, even after study treatment stopped in HPS, benefits persisted for at least 5 years without any evidence of emerging hazards. These findings provide further support for the prompt initiation and long-term continuation of statin treatment.Funding UK Medical Research Council, British Heart Foundation, Merck & Co, Roche Vitamins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“a timeframe during which a clinical benefit of lipid-lowering therapy would not be expected to emerge 10”
From Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis (2016) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Heart Protection Study and Cholesterol Treatment Trialists’ Collaborators meta-analyses have demonstrated that statins provide consistent cardiovascular benefits and all-cause mortality reduction for patients [6, 7].”
In the citing paper
“Beneficial effects are retained over longterm follow-up.427”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [427]
In the citing paper
“However, in managing dyslipidemia expressed by hypertriglyceridemia, the non-HDL-C level is more useful than the LDL-C level. This has been reported in a number of studies177–179, 623, 624, 626, 627, 647).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [627]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Report of the Conference on Low Blood Cholesterol: Mortality Associations.
Jacobs, D. R., Blackburn, H., HIGGINS, M. W., REED, D. M., Iso, H., McMillan, G. C., Neaton, J. D., Nelson, J., Potter, J., & Rifkind, B. M. (1992) · Circulation · doi:10.1161/01.cir.86.3.1046 · Cited by 720
Long-term follow-up of the West of Scotland Coronary Prevention Study
Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P. W., & Cobbe, S. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065994 · Cited by 416
Carcinogenicity of Lipid-Lowering Drugs
Newman, T. B. (1996) · JAMA · doi:10.1001/jama.1996.03530250059028 · Cited by 378
Should there be a moratorium on the use of cholesterol lowering drugs?
Smith, G. D., & Pekkanen, J. (1992) · British medical journal · doi:10.1136/bmj.304.6824.431 · Cited by 357
Holdaas, H., Fellström, B., Cole, E., Nyberg, G., OLSSON, A. G., Pedersen, T. R., Madsen, S., Grönhagen‐Riska, C., Neumayer, H. ‐., Maes, B., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01105.x · Cited by 346
Strandberg, T. E., Pyörälà, K., Cook, T. J., Wilhelmsen, L., Færgeman, O., Þorgeirsson, G., Pedersen, T. R., & KJEKSHUS, J. K. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16936-5 · Cited by 329
Cited by
Sorted by citations
Items 301–377 of 377
Why Do We Still Need Large Scale Clinical Trial: The Case of n−3 PUFA
Marchioli, R., & Levantesi, G. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00202 · Cited by 2
Cela, L. R., Santana-Martínez, S., García-Ramos, M., Bergamino, M., García-Giustiniani, D. A., Vélez, P., Hernández, J. L., García‐Ibarbia, C., González‐Bustos, P., Ruíz-Martín, P., et al. (2022) · The Pharmacogenomics Journal · doi:10.1038/s41397-022-00274-8 · Cited by 3
Li, Y., Sun, M., Li, R., Dou, M., Dong, H., Xue, L., & Sun, G. (2023) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.23-45 · Cited by 4
Safety Considerations of Pharmacological Treatment
Kim, K., & Choi, S. H. (2021) · Stroke revisited · doi:10.1007/978-981-16-3923-4_17 · Cited by 2
Cholesterol: a Century of Research and Debate
Mathew, B. C., & Daniel, R. S. (2008) · Libyan Journal of Medicine · doi:10.3402/ljm.v3i2.4757 · Cited by 2
Reducing exposure to cardiovascular risk factors: the legacy of prevention
Arsenault, B. J., & Puri, R. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.08.83 · Cited by 2
Deprescribing: a challenge for clinical cardiologists
Dolara, A. (2019) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2019.1593286 · Cited by 2
Wang, Y., Wang, A., Li, Z., Li, Z., Hu, B., Li, X., Zheng, H., Hu, H., Hu, H., Nie, Z., et al. (2020) · Trials · doi:10.1186/s13063-020-04741-0 · Cited by 2
Hypertriglyceridaemia: Contemporary management of a neglected cardiovascular risk factor
Khan, T. Z., Schatz, U., Bornstein, S. R., & Barbir, M. (2021) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2021.19 · Cited by 2
The case for more intensive use of statins
Fulcher, J., & KEECH, A. C. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312454045 · Cited by 2
Lovastatin for lowering lipids
Adams, S. P., Alaeiilkhchi, N., & Wright, J. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014858 · Cited by 1
Demographic Predictors of Elevated LDL Cholesterol in Type 1 Diabetes: A Cross-Sectional Study
Dart, M. E., Patrie, J. T., & Love, K. M. (2024) · Clinical Diabetes · doi:10.2337/cd24-0051 · Cited by 1
Jujo, K., Ueshima, D., Abe, T., Shimazaki, K., Fujimoto, Y., Tanaka, T., Murata, T., Miyazaki, T., Matsumoto, M., Tokuyama, H., et al. (2024) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2024.100481 · Cited by 1
Gammon, K. (2013) · Nature · doi:10.1038/493s14a · Cited by 1
Controversies in dyslipidaemia management
Stock, J. K. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.036 · Cited by 1
Statines : des informations disponibles à la prescription courante…
Durand, D. V. (2013) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2013.11.004 · Cited by 1
Ушкалова, Е. А., Tkacheva, O. N., Рунихина, Н. К., Чухарева, Н. А., & Bevz, A. Y. (2016) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2016-12-3-351-358 · Cited by 1
Suckow, B. D., & Goodney, P. P. (2017) · Difficult decisions in surgery: an evidence-based approach · doi:10.1007/978-3-319-33293-2_40 · Cited by 1
Song, Y. S., Oh, T. J., Kim, K. M., Moon, J. H., Choi, S. H., Jang, H. C., Park, K. S., & Lim, S. K. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.1.38 · Cited by 1
Evaluation of the effectiveness of lipid-lowering agents
Шевко, В. Г., Galas, M. A., Леонидович, Г. Т., & Колбин, А. С. (2020) · The Scientific Notes of the Pavlov University · doi:10.24884/1607-4181-2019-26-3-78-85 · Cited by 1
Sallam, M., Hassan, H., Connolly, D. L., & Rahman, M. S. (2024) · European Cardiology Review · doi:10.15420/ecr.2024.06 · Cited by 1
Transient Visual Loss or Blurring
Tamhankar, M. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-34044-1.00010-9 · Cited by 1
Yuan, L. (2022) · CRC Press eBooks · doi:10.1201/b22816-9 · Cited by 1
Relationship Between Plaque Echogenicity and Atherosclerosis Biomarkers
Kakisis, J. D., Avgerinos, E. D., Kadoglou, N. P. E., Sfyroeras, G. S., Moulakakis, K. G., & Liapis, C. D. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7425-8_20 · Cited by 1
Are the benefits of statins a class effect?
Wright, J. M. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.050236 · Cited by 1
Aspectos socioeconómicos de la mortalidad en el Pacífico colombiano
Romero-Prieto, J. E. (2016) · doi:10.32468/dtseru.240 · Cited by 1
The Four Secrets the Drug Companies Don't Want You to Know
LaMattina, J. L. (2012) · Wiley eBooks · doi:10.1002/9781118511329.ch1
Ryan, R. P. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
Onkologie und Versorgung in Fach- und Publikumsmedien
Gaisser, A. (2013) · Der Onkologe · doi:10.1007/s00761-013-2580-3
Masuo, K. (2015) · InTech eBooks · doi:10.5772/59862 · Cited by 2
Lipidtherapie beim geriatrischen Patienten
Lechleitner, M. (2013) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Safety of long-term simvastatin discontinuation
Puccetti, L., Scarpini, F., Cappellone, R., & Auteri, A. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60719-3
Response to Letters Regarding Article, “Statins and the Risk of Cancer After Heart Transplantation”
Fröhlich, G., Enseleit, F., Wolfrum, M., von Babo, M., Frank, M., Berli, R., Hermann, M., Holzmeister, J., Noll, G., Lüscher, T. F., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.147595
Ainsworth, S. (2011) · Nurse Prescribing · doi:10.12968/npre.2011.9.12.581
Schmedt, N., & Garbe, E. (2013) · Circulation · doi:10.1161/circulationaha.112.135707
The cardiovascular health of the nation - should we be advocating a low-carbohydrate, high-fat diet?
Raal, F. J. (2012) · South African Medical Journal · doi:10.7196/samj.6049
Safety of long-term simvastatin discontinuation – Authors' reply
Bulbulia, R. A., Armitage, J., & Collins, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60720-x
The Current Status of Statins in Stroke Prevention
Moonis, M. (2014) · Journal of Neurology & Stroke · doi:10.15406/jnsk.2014.01.00014
Fitch, K., Goldberg, S. W., Iwasaki, K., Pyenson, B. S., Kuznik, A., & Solomon, H. A. (2009) · Europe PMC (PubMed Central)
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
No Evidence of Adverse Outcomes from Long-Term Statin Therapy
Soloway, B. (2011) · Journal watch · doi:10.1056/jw201112200000003
Genetic association study of plasma creatine kinase levels in the Montreal Heart
Zetler, R. Z. (2014)
From statin efficacy to everyday effectiveness: Studying the gap in between.
Ruokoniemi, P. T. (2015) · UTUPub (University of Turku)
Statins: Risk-Benefits and Role in Treating Dyslipidemias
Gotto, A. M., & Moon, J. E. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_24
PERSPECTIVES IN CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Statins and Colorectal Cancer
Lochhead, P. J., & Chan, A. T. (2013)
Lipidsenkende Therapie bei geriatrischen Patienten
Lechleitner, M. (2013) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-013-0516-6
Almuwaqqat, Z., Hung, O. Y., & Parashar, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803547-4.00014-8
Statins and Cancer Survivors: the Need for Structured Guidelines
Almuwaqqat, Z., Hung, O. Y., & Parashar, S. (2017) · Future Cardiology · doi:10.2217/fca-2017-0085
Pharmacological treatment for dyslipidemia
Tsukamoto, K. (2018) · Journal of the Japanese Coronary Association · doi:10.7793/jcoron.24.005
Onkologie und Versorgung in Fach- und Publikumsmedien
(KID), K., & Gaisser, A. (2018) · Der Onkologe · doi:10.1007/s00761-018-0383-2
Chronic limb-threatening ischaemia - Prognosis after intervention
Baubeta, E. (2019)
Onuegbu, A., Roy, S. K., & Budoff, M. J. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.10.003
Was bringt die Lipidtherapie langfristig?
Füessl, H. S. (2012) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-012-0441-4
Anti-PCSK9 Vaccines - An Emerging Therapeutic Innovative Game Changer in Dyslipidemia and Beyond
Das, M. K., Sinha, T., & Chaudhary, M. K. (2020) · American Journal of Internal Medicine · doi:10.11648/j.ajim.20200806.11
Pedro‐Botet, J., Climent, E., & Benaiges, D. (2020) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(20)30024-8
The Role of Statins in the Metabolic Syndrome
Nilsson, P. M. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1331-8_10
(2012) · Pharmaceutical Medicine · doi:10.1007/bf03256901
(2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.200
Chen, L., Zhong, J., Ye, Z., Chen, Q., Ye, M., Yan, Y., & Luo, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-235797/v1
Dewi, D. R., Santhi, D. D. D., Sukrama, D., & Karsana, A. R. (2018) · INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY · doi:10.24293/ijcpml.v20i2.1076
Basis- und spezielle Labordiagnostik
Hafer, C., & Elitok, S. (2023) · Springer eBooks · doi:10.1007/978-3-662-65648-8_5
About Randomized Clinical Trials Related to Lipoproteins in Diabetes Mellitus
KEECH, A. C., Jenkins, A. J., Gebski, V., & Marschner, I. C. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_20
Low Vitamin D Status Attenuates Hypolipidemic and Pleiotropic Effects of Atorvastatin in Women
Krysiak, R. G., Kowalcze, K. E., Szkróbka, W., & Okopień, B. (2025) · Nutrients · doi:10.3390/nu17101674
Xu, Z., Fang, Y., Peng, Y., Zhang, C., & Zheng, C. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5266617
Xu, Z., Fang, Y., Peng, Y., Zhang, C., & Zheng, C. (2025) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484251361059
Goljan, E., Abouelhoda, M., Tahir, A. I., ElKalioby, M., Meyer, B. F., & Monies, D. (2024) · Figshare · doi:10.6084/m9.figshare.26697140
Goljan, E., Abouelhoda, M., Tahir, A. I., ElKalioby, M., Meyer, B. F., & Monies, D. (2024) · Figshare · doi:10.6084/m9.figshare.25469193
Goljan, E., Abouelhoda, M., Tahir, A. I., ElKalioby, M., Meyer, B. F., & Monies, D. (2024) · Figshare · doi:10.6084/m9.figshare.26697143
Goljan, E., Abouelhoda, M., Tahir, A. I., ElKalioby, M., Meyer, B. F., & Monies, D. (2024) · Figshare · doi:10.6084/m9.figshare.26697146
Goljan, E., Abouelhoda, M., Tahir, A. I., ElKalioby, M., Meyer, B. F., & Monies, D. (2024) · Figshare · doi:10.6084/m9.figshare.25469138
Bianchi, M., & Conti, G. R. (2023) · Pharmaceutical Sciences and Drug Design · doi:10.51847/ssavizm3gj
Feng, Y., Liu, M., Shi, Y., Yi, Y., Xu, X., Ma, K., Wang, K., & Wang, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1729426
Pharmacological interventions of metabolic therapies
Ruan, C., & Hua, Y.-J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34186-1.00003-7
Polyakova, E. A., & Zaslavskaya, E. L. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-7061
Chen, X., Zou, M., Chen, Z., Wu, J., Wu, G., Zhou, Z., Xu, R., Li, N., Feng, W., Guo, Z., et al. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103762
About Randomised Clinical Trials Related to Lipoproteins in Diabetes Mellitus
KEECH, A. C., Jenkins, A. J., & Gebski, V. (2013) · Contemporary diabetes · doi:10.1007/978-1-4614-7554-5_17
Der frühe Nutzen lässt sich bei späterer Gabe nicht mehr aufholen
Diener, H. (2012) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-012-0085-z
Metadata
- Authors
- Heart Protection Study Collaborative Group
- Corresponding author
- Heart Protection Study Collaborative Group
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 378
- Issue
- 9808
- Pages
- 2013-2020
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC3242163
- OpenAlex
- W2133184701
- Cited by
- 373
- References
- 17
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 15 · 2023: 17 · 2022: 14 · 2021: 13 · 2020: 14 · 2019: 20 · 2018: 25 · 2017: 17 · 2016: 28 · 2015: 29 · 2014: 27 · 2013: 41 · 2012: 38
- FWCI
- 38.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- British Heart Foundation
- Medical Research Council (MC_EX_G0801669)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- statin therapy, simvastatin, LDL cholesterol lowering, long-term efficacy, vascular death, major vascular events, cancer incidence, post-trial follow-up, Heart Protection Study, high-risk patients, statin safety, lipid-lowering therapy, secondary prevention of cardiovascular disease, long-term follow-up, cardiovascular risk reduction
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cholesterol, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Myocardial Revascularization, Neoplasms, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
